| Tag | Content |
|---|---|
| UniProt Accession | ERBB2_HUMAN; P04626; |
| Entrez ID | 2064 |
| GenBank Protein ID | NM_001005862.2; NM_001289936.1; NM_001289938.1; NM_004448.3; |
| GenBank Nucleotide ID | NP_001005862.1; NP_001276865.1; NP_001276867.1; NP_004439.2; |
| Protein Name | Receptor tyrosine-protein kinase erbB-2 (EC 2.7.10.1) (Metastatic lymph node gene 19 protein) (MLN 19) (Proto-oncogene Neu) (Proto-oncogene c-ErbB-2) (Tyrosine kinase-type cell surface receptor HER2) (p185erbB2) (CD antigen CD340) |
| Gene Name | ERBB2; HER2; MLN19; NEU; NGL |
| Organism | Homo sapiens |
| NCBI Taxa ID | 9606 |
| Functional Description | Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Regulates outgrowth and stabilization of peripheral microtubules (MTs). Upon ERBB2 activation, the MEMO1-RHOA-DIAPH1 signaling pathway elicits the phosphorylation and thus the inhibition of GSK3B at cell membrane. This prevents the phosphorylation of APC and(view all) |
| Sequence (Fasta) | MELAALCRWG LLLALLPPGA ASTQVCTGTD MKLRLPASPE THLDMLRHLY QGCQVVQGNL 60 ELTYLPTNAS LSFLQDIQEV QGYVLIAHNQ VRQVPLQRLR IVRGTQLFED NYALAVLDNG 120 DPLNNTTPVT GASPGGLREL QLRSLTEILK GGVLIQRNPQ LCYQDTILWK DIFHKNNQLA 180 LTLIDTNRSR ACHPCSPMCK GSRCWGESSE DCQSLTRTVC AGGCARCKGP LPTDCCHEQC 240 AAGCTGPKHS DCLACLHFNH SGICELHCPA LVTYNTDTFE SMPNPEGRYT FGASCVTACP 300 YNYLSTDVGS CTLVCPLHNQ EVTAEDGTQR CEKCSKPCAR VCYGLGMEHL REVRAVTSAN 360 IQEFAGCKKI FGSLAFLPES FDGDPASNTA PLQPEQLQVF ETLEEITGYL YISAWPDSLP 420 DLSVFQNLQV IRGRILHNGA YSLTLQGLGI SWLGLRSLRE LGSGLALIHH NTHLCFVHTV 480 PWDQLFRNPH QALLHTANRP EDECVGEGLA CHQLCARGHC WGPGPTQCVN CSQFLRGQEC 540 VEECRVLQGL PREYVNARHC LPCHPECQPQ NGSVTCFGPE ADQCVACAHY KDPPFCVARC 600 PSGVKPDLSY MPIWKFPDEE GACQPCPINC THSCVDLDDK GCPAEQRASP LTSIISAVVG 660 ILLVVVLGVV FGILIKRRQQ KIRKYTMRRL LQETELVEPL TPSGAMPNQA QMRILKETEL 720 RKVKVLGSGA FGTVYKGIWI PDGENVKIPV AIKVLRENTS PKANKEILDE AYVMAGVGSP 780 YVSRLLGICL TSTVQLVTQL MPYGCLLDHV RENRGRLGSQ DLLNWCMQIA KGMSYLEDVR 840 LVHRDLAARN VLVKSPNHVK ITDFGLARLL DIDETEYHAD GGKVPIKWMA LESILRRRFT 900 HQSDVWSYGV TVWELMTFGA KPYDGIPARE IPDLLEKGER LPQPPICTID VYMIMVKCWM 960 IDSECRPRFR ELVSEFSRMA RDPQRFVVIQ NEDLGPASPL DSTFYRSLLE DDDMGDLVDA 1020 EEYLVPQQGF FCPDPAPGAG GMVHHRHRSS STRSGGGDLT LGLEPSEEEA PRSPLAPSEG 1080 AGSDVFDGDL GMGAAKGLQS LPTHDPSPLQ RYSEDPTVPL PSETDGYVAP LTCSPQPEYV 1140 NQPDVRPQPP SPREGPLPAA RPAGATLERP KTLSPGKNGV VKDVFAFGGA VENPEYLTPQ 1200 GGAAPQPHPP PAFSPAFDNL YYWDQDPPER GAPPSTFKGT PTAENPEYLG LDVPV 1256 |
|
||||||||||||||||||||||||||||||||||||||||||||||
| Database | Annotation |
|---|---|
| Cancer Gene Census | breast, ovarian, other tumour types, NSCLC, gastric |
| CTD (Curated) (count: 28) (view all) | MESH:D000230
; Adenocarcinoma MESH:D001943 ; Breast Neoplasms MESH:D063646 ; Carcinogenesis MESH:D002280 ; Carcinoma, Basal Cell MESH:D018270 ; Carcinoma, Ductal, Breast MESH:D002292 ; Carcinoma, Renal Cell |
| DisGeNet (Curated) (count: 31) (view all) | C0001418; Adenocarcinoma
C0007117; Basal cell carcinoma C0007120; Bronchioloalveolar Adenocarcinoma C0007134; Renal Cell Carcinoma C0009375; Colonic Neoplasms C0014474; Ependymoma |
| HGMD (count: 2) | CM004332; Breast cancer, increased risk, association with; Missense/nonsense
CM087578; Lung cancer, incr. risk in females, non-smokers and non-drinkers; Missense/nonsense |
| GWASdb (count: 7) (view all) | rs2934971; Urinary metabolites; kidney disease
rs2952155; Asthma; asthma rs1810132; Asthma; asthma rs4252627; Asthma; asthma rs1136201; Drug response to Trastuzumab; Null rs1136201; Tooth agenesis (mandibular third molar); tooth agenesis |
| PTM | Modification Sites |
|---|---|
| Phosphorylation (count: 52) (view all) | 1002 GPASPLDSTFYRSLL dbPAF
1003 PASPLDSTFYRSLLE dbPAF 1005 SPLDSTFYRSLLEDD dbPAF 1007 LDSTFYRSLLEDDDM dbPAF 1023 DLVDAEEYLVPQQGF dbPAF 1049 MVHHRHRSSSTRSGG dbPAF |
| Ubiquitination (count: 9) (view all) | 150 RSLTEILKGGVLIQR PLMD
175 LWKDIFHKNNQLALT PLMD 591 CVACAHYKDPPFCVA PLMD 724 ETELRKVKVLGSGAF PLMD 736 GAFGTVYKGIWIPDG PLMD 747 IPDGENVKIPVAIKV PLMD |